Reference Institute for Bioanalytics

Recent papers from Reference Institute for Bioanalytics

1. Commutability assessment of candidate reference materials for total bilirubin assays in neonatesClinical Chemistry and Laboratory Medicine (CCLM) · 2026
2. Creatinine assay interferences compromises MELD accuracy and may bias liver allocationNature Communications · 2026
3. How many laboratories are necessary? Analytical assessment of precision and reproducibility in disinfectant efficacy testing for quantifying the impact of laboratory number on result reliability2026
4. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection FractionJournal of the American College of Cardiology · 2022
5. Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD‐ONPediatric Pulmonology · 2026
6. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood PressureJournal of the American College of Cardiology · 2021
7. Results of red cell antibody screening assays from 2,500 laboratories in 10 external quality assessment programs: sensitivity for anti-D.2026
8. Result harmonization in medical laboratories: accomplishments and challengesClinical Chemistry and Laboratory Medicine (CCLM) · 2026
9. Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐ReducedEuropean Journal of Heart Failure · 2025
10. Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to AntidepressantsThe Journal of Clinical Psychiatry · 2025
11. Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.2025
12. Validation of the Japan Society of Clinical Chemistry (JSCC) recommended reference measurement procedure for glycated albumin determinationAnnals of Clinical Biochemistry International Journal of Laboratory Medicine · 2025
13. The Path to Clinical Implementation of DPYD Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing CenterOncology Research and Treatment · 2025
14. A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young AdultsJournal of the Endocrine Society · 2025
15. Toward Origami-Inspired In Vitro Cardiac Tissue ModelsACS Biomaterials Science & Engineering · 2025
16. Regulatory Guidelines for the Analysis of Therapeutic Peptides and ProteinsJournal of Peptide Science · 2025
17. Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ONLung · 2025
18. Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratoriesClinical Chemistry and Laboratory Medicine (CCLM) · 2025
19. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participantsClinical Chemistry and Laboratory Medicine (CCLM) · 2025
20. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part I – EQA in general and EQA programs in particularClinical Chemistry and Laboratory Medicine (CCLM) · 2025